Parexel, one of the world’s largest clinical trial organizations (CROs) offering a full diversity of Phase I-IV clinical progression services, and the Japan Cancer Research Foundation (JFCR), the first and leading non-profit cancer research organization in Japan. , today announced a strategic alliance to boost oncology clinical trials in Japan.
As part of the agreement, JFCR will enroll in Parexel’s Global Site Alliance network, making it a popular site for oncology clinical trials and offering more opportunities for Japanese patients to participate in cancer research. Parexel will leverage JFCR’s expertise to help sponsors scale up protocols. that are more aligned with Japan’s care criteria and regulatory approval processes, streamlining patient recruitment and testing rollouts.
“Consistent with global trends, the incidence of cancer is expected to increase in Japan,” said Shigehiro Miki, Parexel Corporate Vice President and General Manager of Japan. “We look forward to JFCR joining Parexel’s Site Alliance Network and working together to eliminate barriers and increase the access of potentially life-changing treatments to Japanese patients.”
With more than 115 years of experience, JFCR is Japan’s first and largest medical organization committed to cancer care. The organization is known for its holistic, multifunctional cancer center, state-of-the-art study facilities, and the gigantic number of patients it serves. JFCR’s healing expertise, combined with Parexel’s clinical trials, will enable both organizations to successfully recruit Japanese patients, who are underrepresented in oncology studies, while expanding cancer care functions in Japan.
“Parexel and JFCR are entering into this strategic alliance driven by a shared sense of urgency to enable sponsors to conduct trials in Japan and ensure those patients have cutting-edge clinical research,” said Takeshi Sano, MD, PhD, FRCS, Hospital Director, Cancer Hospital Institute. JFCR. Improving the well-being of others around the world through the defeat of cancer is the central tenet of JFCR. We look forward to greatly collaborating with Parexel to bring our principle to life. ”
Parexel’s Site Alliance Network is designed to provide a strategic technique for on-site responses to address critical demanding situations in the clinical trial process, recruit patients more efficiently, and expand clinical trial opportunities for researchers and patients around the world. The network includes more than 480 sites representing approximately 21,000 researchers worldwide.
Parexel’s strategic alliance agreement with JFCR is an extension of its efforts to drive clinical innovation in key curative areas, such as oncology, in the Asia/Pacific region. Parexel maintains relationships with other leading alliance sites in the region, adding Kyoto University Hospital, Osaka International Cancer Institute, Beijing Illness Challenge Foundation, and the Chinese Academy of Medical Sciences of Cancer Hospitals.